You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

254 Results
Document
New
Jan 2025
Document
New
Jan 2025
Document
New
Jan 2025
Document
New
Jan 2025
Document
New
Jan 2025
Scientist, Cancer Screening – Program Design, Acute and Hospital-Based Care, Ontario Health Behavioural Scientistdiego.llovet@ontariohealth.ca
Chercheur, Cancer Screening – Program Design, Soins aigus et hospitaliers, Santé Ontario Spécialiste des sciences du comportementdiego.llovet@...
Drug
Other Name(s): Imfinzi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
oxaliplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Drug
Other Name(s): Sprycel®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Firmagon®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025

Pages